Expert Review of Molecular Diagnostics最新文献_第7页

Integrating epigenetic and immune biomarkers to enable dynamic precision therapy in triple-negative breast cancer. 整合表观遗传和免疫生物标志物，实现三阴性乳腺癌的动态精确治疗。

IF 3.6 3区医学

Expert Review of Molecular Diagnostics Pub Date : 2026-03-01 Epub Date: 2026-04-16 DOI: 10.1080/14737159.2026.2646564

Jabed Iqbal, Sue-Zann Chua

引用次数: 0

Cell-free HPV DNA as a complementary biomarker to imaging in HPV-associated oropharyngeal squamous cell carcinoma: a narrative synthesis of key studies. 无细胞HPV DNA作为HPV相关口咽鳞状细胞癌成像的补充生物标志物：关键研究的叙事综合

IF 4.3 3区医学

Expert Review of Molecular Diagnostics Pub Date : 2026-03-01 Epub Date: 2026-04-24 DOI: 10.1080/14737159.2026.2661735

Ingeborg Tinhofer, Franziska Hausmann

{"title":"Cell-free HPV DNA as a complementary biomarker to imaging in HPV-associated oropharyngeal squamous cell carcinoma: a narrative synthesis of key studies.","authors":"Ingeborg Tinhofer, Franziska Hausmann","doi":"10.1080/14737159.2026.2661735","DOIUrl":"10.1080/14737159.2026.2661735","url":null,"abstract":"Introduction: Human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) represents a biologically distinct disease entity with superior prognosis compared with HPV-negative head and neck cancers. While imaging-based strategies, particularly those monitoring hypoxia, have emerged as promising tools for response-guided de-escalation, they may not fully capture tumor biology or residual disease risk. Consequently, circulating tumor-derived HPV DNA (ctHPV-DNA) has gained attention as a minimally invasive biomarker with potential to complement imaging for treatment monitoring and surveillance.Areas covered: This review synthesizes data from studies published over the past decade that evaluated the clinical utility of ctHPV-DNA assessment. Evidence is summarized for pretreatment detection, on-treatment kinetics, postoperative minimal residual disease, and longitudinal surveillance, with emphasis on the complementarity between molecular and imaging markers.Expert opinion: Across cohorts, ctHPV-DNA mirrors tumor burden, clears with effective therapy, and often signals recurrence months before radiologic confirmation. Two consecutive positive tests may identify relapse and justify targeted imaging, whereas persistently negative serial tests provide strong reassurance. Although prognostic, the clinical benefit of ctHPV-DNA -guided management remains to be proven in prospective randomized trials. Standardization of assays and integration with imaging workflows will determine whether molecularly anchored surveillance becomes a quality benchmark in HPV-associated OPSCC care.","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":" ","pages":"257-266"},"PeriodicalIF":4.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What is the future of nanoparticles as a clinical theranostic tool for glioblastoma? 纳米颗粒作为胶质母细胞瘤临床治疗工具的前景如何？

IF 4.3 3区医学

Expert Review of Molecular Diagnostics Pub Date : 2026-03-01 Epub Date: 2026-04-08 DOI: 10.1080/14737159.2026.2656353

Maxim Shevtsov, Viacheslav Fedorov, Natalia Yudintceva, Arina Ilina, Haneef Ahmed Amissah, Georgii Fofanov, Elena Oganesyan, Gabriel Opoku, Tawfeek Ahmed Amissah, Stephanie E Combs

{"title":"What is the future of nanoparticles as a clinical theranostic tool for glioblastoma?","authors":"Maxim Shevtsov, Viacheslav Fedorov, Natalia Yudintceva, Arina Ilina, Haneef Ahmed Amissah, Georgii Fofanov, Elena Oganesyan, Gabriel Opoku, Tawfeek Ahmed Amissah, Stephanie E Combs","doi":"10.1080/14737159.2026.2656353","DOIUrl":"10.1080/14737159.2026.2656353","url":null,"abstract":"Introduction: Despite a combined approach to manage malignant brain tumors (including glioblastoma), which includes surgical removal of the tumor followed by cycles of radiotherapy and chemotherapy, patient survival remains extremely low. Advances in nanotechnology in recent decades offer hope for the use of nanoscale agents for the successful diagnosis and treatment of brain tumors.Areas covered: This review analyzes the results of preclinical and clinical studies of nanoparticles of various physico-chemical compositions (e.g. SPIONs, AuNPs, QDs, etc) in the diagnosis and therapy (theranostics) of brain tumors. Particular attention is paid to the challenges of targeted drug delivery, antitumor activity, and future development strategies in this field.Expert opinion: Nanoscale agents of diverse physicochemical compositions have demonstrated transformative potential in the diagnosis and treatment of brain tumors, bridging the gap between bench research and clinical application. By enabling precise imaging, targeted delivery, and real-time therapeutic monitoring, nanotechnology offers a multifaceted platform for advancing personalized neuro-oncology. Further interdisciplinary research, standardization of preclinical protocols, and carefully designed clinical trials will be vital in translating these advances into tangible clinical benefits. Nanoparticle-based theranostics are poised to redefine the therapeutic landscape of brain tumors moving from broad cytotoxicity toward targeted, adaptive, and patient-centered treatment paradigms.","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":" ","pages":"201-222"},"PeriodicalIF":4.3,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147618631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic value of dynamic sST2 and immune-coagulation biomarkers in severe community-acquired pneumonia: insights from a prospective cohort study. 动态sST2和免疫凝血生物标志物在严重社区获得性肺炎中的预后价值：一项前瞻性队列研究的见解

IF 4.3 3区医学

Expert Review of Molecular Diagnostics Pub Date : 2026-02-01 Epub Date: 2026-03-29 DOI: 10.1080/14737159.2026.2651164

Shanshan Liu, Jian Dong, Jia Hao Wu

{"title":"Prognostic value of dynamic sST2 and immune-coagulation biomarkers in severe community-acquired pneumonia: insights from a prospective cohort study.","authors":"Shanshan Liu, Jian Dong, Jia Hao Wu","doi":"10.1080/14737159.2026.2651164","DOIUrl":"10.1080/14737159.2026.2651164","url":null,"abstract":"Background: Effective risk stratification in community-acquired pneumonia (CAP) remains challenging. We evaluated soluble suppression of tumorigenicity 2 (sST2) dynamics for predicting 90-day all-cause mortality and hospital readmission.Methods: Prospective cohort of 146 severe CAP, 135 mild CAP patients, and 50 controls. Serum sST2 measured at admission and pre-discharge. with dynamic changes (ΔsST2 = T2 - T1) calculated. The primary endpoints were 90-day all-cause mortality and 90-day all-cause readmission, Predictive models 1for each endpoint, including sST2-based and traditional clinical scores, were compared using area under the receiver operating characteristic curve (AUC), Brier score, and decision curve analysis (DCA).Results: Admission sST2 distinguished severity (AUC = 0.780). A pre-discharge model (sST2, D-dimer, lymphocyte percentage) predicted mortality superiorly (AUC = 0.79) versus clinical scores (PSI:0.69, p = 0.038; SOFA:0.66, p = 0.015). Admission sST2 independently predicted mortality (HR = 1.89, p = 0.003).High sST2 strongly predicted readmission at both T1 and T2. especially in the early to intermediate follow-up period.Conclusions: sST2 dynamics significantly enhance CAP risk stratification. The discharge-phase biomarker model outperforms conventional scores,a model using D-dimer, procalcitonin, and lymphocyte percentage is a practical alternative. Integrating recovery-phase biomarkers into discharge planning offers a precision medicine strategy to optimize post-discharge management and reduce adverse outcomes.","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":" ","pages":"173-190"},"PeriodicalIF":4.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147503624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Translation of scRNA-seq to a clinical blood test for infection diagnostics. scRNA-Seq转化为感染诊断的临床血液检测。

IF 4.3 3区医学

Expert Review of Molecular Diagnostics Pub Date : 2026-02-01 Epub Date: 2026-04-02 DOI: 10.1080/14737159.2026.2647154

Nelson L S Tang, Tsz-Ki Kwan, Jinghan Huang, Michael L H Tang, Ho-Yin Ho, Xingyan Wang, Christopher K C Lai, Grace C Y Lui, Suk-Ling Ma, Kwong-Sak Leung

{"title":"Translation of scRNA-seq to a clinical blood test for infection diagnostics.","authors":"Nelson L S Tang, Tsz-Ki Kwan, Jinghan Huang, Michael L H Tang, Ho-Yin Ho, Xingyan Wang, Christopher K C Lai, Grace C Y Lui, Suk-Ling Ma, Kwong-Sak Leung","doi":"10.1080/14737159.2026.2647154","DOIUrl":"10.1080/14737159.2026.2647154","url":null,"abstract":"Introduction: Early and accurate triage of patients with febrile illness is crucial for appropriate treatment. While standard inflammatory biomarkers are often nonspecific, transcriptome analysis of peripheral blood has diagnostic potential. However, bulk gene expression data is often confounded by changes in cell count proportions, a more robust quantification of gene expression in specific single-cell types, such as monocytes, is required to serve as a reliable clinical biomarker.Areas covered: Various methods to obtain single-cell-type gene expression results, including the gold standard of gene expression analysis after cell sorting and single-cell RNA sequencing, which are difficult to implement in the routine settings are discussed. Other method to interrogate gene expression of a single cell-type is needed. Finally, monocyte cell-type specific ratio-based biomarker (RBB, called Direct Leukocyte Single cell-type Transcript Abundance, or DIRECT LS-TA) which can estimate single cell-type (monocyte) specific gene expression without cell sorting is introduced.Expert opinion: Traditional diagnostic test for differentiating infection has several limitations requiring breakthrough including turn-around time and cost. DIRECT LS-TA provides a reliable way to quantify monocyte-specific gene expression that strongly correlates with gold-standard methods. It is more affordable than single-cell RNA sequencing and can be readily implemented in clinical laboratories using widely available quantitative PCR or digital PCR machines.","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":" ","pages":"113-126"},"PeriodicalIF":4.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147591146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beyond the laboratory: how COVID-19 reshaped specimen collection, testing workflows, and diagnostic algorithms. 超越实验室：COVID-19如何重塑标本采集、测试工作流程和诊断算法。

IF 4.3 3区医学

Expert Review of Molecular Diagnostics Pub Date : 2026-02-01 Epub Date: 2026-02-27 DOI: 10.1080/14737159.2026.2638743

Alexander Domnich, Elena Pariani

{"title":"Beyond the laboratory: how COVID-19 reshaped specimen collection, testing workflows, and diagnostic algorithms.","authors":"Alexander Domnich, Elena Pariani","doi":"10.1080/14737159.2026.2638743","DOIUrl":"10.1080/14737159.2026.2638743","url":null,"abstract":"Introduction: The SARS-CoV-2 pandemic forced a radical expansion of essential public health laboratory services that went beyond basic testing. This perspective highlights key shifts in laboratory function, specifically toward decentralized testing, self-sampling, less invasive specimen types, point-of-care devices, and novel surveillance strategies.Areas covered: The surge in testing demand favored decentralized solutions, including rapid lateral flow tests, due to their flexibility, speed, and affordability. However, several challenges arose from the variable diagnostic accuracy of rapid self-tests and alternative specimen types when compared to reference laboratory-based molecular assays using nasopharyngeal swabs. For instance, the use of self-collected saliva, which is often preferred by patients, was hindered by a lack of internationally standardized processing protocols. A post-pandemic rebound in the circulation of respiratory pathogens other than SARS-CoV-2 was likely driven by both immunity debt and increased testing, including of less severe cases, commonly performed through more costly multiplex respiratory panels.Expert opinion: Moving forward, while over-the-counter self-tests for common respiratory viruses are now common, stricter regulatory oversight and improved data connectivity are essential. Local decision-makers must weigh the trade-offs between broad testing access and clinical performance, and implement robust diagnostic stewardship programs for acute respiratory infections.","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":" ","pages":"127-139"},"PeriodicalIF":4.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147289627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial intelligence in cancer screening: a narrative review of current evidence and future directions. 人工智能在癌症筛查中的应用：对当前证据和未来方向的述评。

IF 4.3 3区医学

Expert Review of Molecular Diagnostics Pub Date : 2026-02-01 Epub Date: 2026-04-26 DOI: 10.1080/14737159.2026.2648127

Yigit Yazarkan, Gamze Sonmez, Taha Koray Sahin, Alessandro Rizzo, Deniz Can Guven

{"title":"Artificial intelligence in cancer screening: a narrative review of current evidence and future directions.","authors":"Yigit Yazarkan, Gamze Sonmez, Taha Koray Sahin, Alessandro Rizzo, Deniz Can Guven","doi":"10.1080/14737159.2026.2648127","DOIUrl":"10.1080/14737159.2026.2648127","url":null,"abstract":"Introduction: Cancer remains one of the leading causes of death worldwide, with outcomes improving significantly when the disease is detected at an early stage. Screening programs have demonstrated clear benefits, yet they often struggle with limited accuracy, unequal participation, and substantial demands on health care systems. Artificial intelligence (AI) has entered this space as a promising tool, aiming to improve detection, reduce workload, and support more individualized screening approaches.Areas covered: This review explores the application of AI across different aspects of cancer screening. We discuss its use in established imaging modalities such as mammography and low-dose CT, explore early developments in liquid and blood-based assays, and highlight efforts to harness routine clinical and laboratory data to better identify people at risk.Expert opinion: AI is beginning to move beyond experimental settings and into real-world clinical practice. Early evidence suggests that it can enhance both accuracy and efficiency. At the same time, important challenges remain, including risks of bias, overdiagnosis, and uneven performance across clinical environments. However, sustainable progress will require robust validation, careful integration into clinical workflows, and policies that ensure the technology benefits patients across diverse settings.","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":" ","pages":"149-172"},"PeriodicalIF":4.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147497986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenges facing genetic diagnostics of Huntington's disease: an update. 亨廷顿舞蹈病基因诊断面临的挑战：最新进展。

IF 4.3 3区医学

Expert Review of Molecular Diagnostics Pub Date : 2026-02-01 Epub Date: 2026-03-19 DOI: 10.1080/14737159.2026.2642712

Larissa Arning, Carsten Saft, Huu Phuc Nguyen

{"title":"Challenges facing genetic diagnostics of Huntington's disease: an update.","authors":"Larissa Arning, Carsten Saft, Huu Phuc Nguyen","doi":"10.1080/14737159.2026.2642712","DOIUrl":"10.1080/14737159.2026.2642712","url":null,"abstract":"Introduction: Since 1993, when a polymorphic CAG trinucleotide repeat was established as the cause of Huntington's disease (HD), fragment analysis has been the first-tier test in genetic diagnosis of HD. However, in recent years it has become increasingly clear that, in addition to the repeat length itself, sequence variations within the HTT repeat and elsewhere in the genome also play a crucial role in the onset and clinical presentation of the disease.Areas covered: Sequence interruptions or non-canonical repeat motifs have historically been difficult to identify, as PCR cannot distinguish an interrupted repeat tract when assessed by capillary electrophoresis. However, these non-canonical interruptions may directly affect the phenotype or result in an underestimation of the uninterrupted CAG repeat length. While next-generation sequencing (NGS) with short read lengths has revolutionized genetic diagnostics, it faces limitations in diagnosing repeat expansion diseases. The literature search methodology involved a review of relevant studies and clinical data.Expert opinion: In contrast, long-read sequencing (LRS) generates read lengths of over 10 kb and can thus overcome the limitations associated with short reads. This enables detailed investigation of repeat sequences and the identification of complex patterns of alternating sequence motifs, potentially providing additional clinically relevant information.","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":" ","pages":"141-147"},"PeriodicalIF":4.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147485186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bringing liquid biopsy to the clinic: diagnostic utility of circulating tumor cells, circulating tumor DNA, and extracellular vesicles in personalized cancer care. 将液体活检带到临床：循环肿瘤细胞、循环肿瘤DNA和细胞外囊泡在个性化癌症治疗中的诊断效用。

IF 3.6 3区医学

Expert Review of Molecular Diagnostics Pub Date : 2026-02-01 Epub Date: 2026-03-30 DOI: 10.1080/14737159.2026.2651162

Nivedita N Kaorey, Julia V Burnier

引用次数: 0

A profile on the Truenat assays for the detection of pulmonary tuberculosis and rifampicin resistance. Truenat检测肺结核和利福平耐药性的概况。

IF 4.3 3区医学

Expert Review of Molecular Diagnostics Pub Date : 2026-02-01 Epub Date: 2026-01-18 DOI: 10.1080/14737159.2026.2616751

Leeberk Raja Inbaraj, Mukesh Kumar Sathya Narayanan, Priya Rajendran, Bella Devaleenal Daniel, Sivakumar Shanmugam, Banurekha Velayutham

{"title":"A profile on the Truenat assays for the detection of pulmonary tuberculosis and rifampicin resistance.","authors":"Leeberk Raja Inbaraj, Mukesh Kumar Sathya Narayanan, Priya Rajendran, Bella Devaleenal Daniel, Sivakumar Shanmugam, Banurekha Velayutham","doi":"10.1080/14737159.2026.2616751","DOIUrl":"10.1080/14737159.2026.2616751","url":null,"abstract":"Introduction: Early diagnosis and treatment initiation are essential to prevent ongoing tuberculosis (TB) transmission and reduce the disease burden. Smear microscopy, which is widely used test for diagnosis, has limited sensitivity and does not detect rifampicin resistance. Truenat is a portable, battery-operated, chip-based test that can be placed in peripheral laboratories, serving as a point-of-care test. It also detects rifampicin resistance, which is crucial in the management of TB.Areas covered: Our review comprehensively covers the functionality and workflow of the Truenat MTB assay, in addition to its cost-effectiveness and diagnostic accuracy, based on recent evidence. We also discuss the merits and drawbacks of alternative diagnostic tests available for detecting TB and rifampicin resistance.Expert opinion: Truenat assays are rapid molecular tests that revolutionized TB diagnosis, moving toward peripheral testing. Evidence indicates that the Truenat MTB Plus performs better than the original Truenat MTB, with an approximate LOD of 30 CFU/ml. The 2025 WHO guidelines rely exclusively on data from Truenat MTB Plus. We need larger studies on the newer Truenat MTB Ultima to evaluate its performance on tongue swabs. Additionally, data on the accuracy of Truenat MTB in children remains scarce, emphasizing the importance of further research in this group. Evidence regarding its accuracy in detecting rifampicin resistance is also limited, requiring larger studies and technological advancements. Truenat MTB will remain crucial in the fight to eliminate TB in the future.","PeriodicalId":12113,"journal":{"name":"Expert Review of Molecular Diagnostics","volume":" ","pages":"101-112"},"PeriodicalIF":4.3,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145951760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0